Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 755-763

  Gurbuz, Venhar ^a,b   Konac, Ece ^a   Varol, Nuray ^a   Yilmaz, Akin ^a   Gurocak, Serhat ^a   Menevse, Sevda ^a   Sozen, Sinan ^a  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Apoptosis; JAK and STAT inhibitors; JAK STAT pathway; Prostate cancer

Indexed keywords

4 [[(4 METHYLPHENYL) SULFONYLOXY] ACETAMIDO] SALICYLIC ACID; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; FLICE INHIBITORY PROTEIN; GELATINASE A; INTERLEUKIN 6; MYELOID LEUKEMIA FACTOR 1; N BENZYL 2 CYANO 3 (3, 4 DIHYDROXYPHENYL) ACRYLAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; JAK STAT3 SIGNALING PATHWAY; NICK END LABELING; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; RNA ISOLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84892994570     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1795     Document Type: Article

References (53)

1. Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, SemmesOJ and Troyer DA: Molecular pathology of prostate cancer. Cancer Biomark 9: 441-459, 2010.
2. Foley R, Hollywood D and Lawler M: Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 11: 477-488, 2004.
3. Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev24: 1967-2000, 2010.
4. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM and Edwards J: Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97: 378-383, 2007.
5. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, etal: Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15: 4815-4822, 2009.
6. Germain D and Frank DA: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13: 5665-5669, 2007.
7. Constantinescu SN, Girardot M and Pecquet C: Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 33: 122-131, 2008.
8. Barton BE, Karras JG, Murphy TF, Barton A and Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther3: 11-20, 2004.
9. Agarwal C, Tyagi A, Kaur M and Agarwal R: Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28: 1463-1470, 2007.
10. Samanta AK, Lin H, Sun T, Kantarjian H and ArlinghausRB: Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468-6472, 2006.
11. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, YonedaK, etal: Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun363: 738-744, 2007.
12. Seo IA, Lee HK, Shin YK, Lee SH, Seo SY, Park JW and Park HT: Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130. Korean J Physiol Pharmacol 13: 131-138, 2009.
13. Shodeinde AL and Barton BE: Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Oncol Targets Ther5: 119-125, 2012.
14. Flowers LO, Subramaniam PS and Johnson HM: A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene24: 2114-2120, 2005.
15. Klampfer L: Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6: 107-121, 2006.
16. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, etal: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
17. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene23: 3550-3560, 2004.
18. Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13: 1362-1366, 2007.
19. Zhang H, Zhang D, Luan X, Xie G and Pan X: Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells. J Int Med Res 38: 1673-1681, 2010.
20. Huang C, Yang G, Jiang T, Huang K, Cao J and Qiu Z: Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res 29: 51, 2010.
21. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM and Bromberg J: Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol27: 4444-4453, 2007.
22. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, BonuccelliG, etal: Stat3 promotes metastatic progression of prostate cancer. Am J Pathol172: 1717-1728, 2008.
23. Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, et al: Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate 72: 82-89, 2012.
24. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, et al: IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene30: 2345-2355, 2011.
25. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA104: 7391-7296, 2007.
26. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT and TurksonJ: A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 79: 1398-1409, 2010.
27. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, etal: A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78: 257-268, 2010.
28. Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD and Lee WM: Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7: 1994-2003, 2008.
29. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene24: 5552-5560, 2005.
30. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, et al: TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer94: 1428-1435, 2006.
31. Liu H, Chen A, Guo F and Yuan L: A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295: 27-37, 2010.
32. Bhattacharya S, Ray RM and Johnson LR: STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 392: 335-344, 2005.
33. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, etal: Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9: 9, 2010.
34. Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, FreudenbergN, et al: Effective targeting of prostate cancer by lymphocytes redirected by a PSMA×CD3 bispecific single-chain diabody. Prostate 71: 588-596, 2011.
35. Kristjansdottir K, Kim K, Choi JS, Horan TC, Brard L, MooreRG and Singh RK: 7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells. Gynecol Oncol126: 252-258, 2012.
36. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
37. Huang C, Huang R, Chang W, Jiang T, Huang K, Cao J, et al: The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma59: 52-61, 2012.
38. Liu X, He Z, Li CH, Huang G, Ding C and Liu H: Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol Oncol Res18: 17-23, 2012.
39. Wang T, Yan XB, Zhao JJ, Ye J, Jiang ZF, Wu DR, et al: Gene associated with retinoid-interferon-induced mortality-19 suppresses growth of lung adenocarcinoma tumor in vitro and in vivo. Lung Cancer 72: 287-293, 2011.
40. Lavecchia A, Di Giovanni C and Novellino E: STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 18: 2359-2375, 2011.
41. Santer FR, Malinowska K, Culig Z and Cavarretta IT: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17: 241-253, 2010.
42. Yu JH, Kim KH and Kim H: Suppression of IL-1beta expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Biochem Pharmacol 72: 1555-1562, 2006.
43. Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, SantavenereE, Alinari L, et al: Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Res 19: 1079-1089, 2009.
44. Shu M, Zhou Y, Zhu W, Wu S, Zheng X and Yan G: Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells. Mol Oncol5: 265-272, 2011.
45. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, JessupJM, et al: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28: 961-972, 2009.
46. Chen W, Shen X, Xia X, Xu G, Ma T, Bai X, et al: NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int32: 70-77, 2012.
47. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, et al: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia12: 39-50, 2010.
48. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, OshiroM, Kothapalli R, et al: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362, 2001.
49. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, et al: Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 65: 10921-10929, 2005.
50. Huang W, Yu LF, Zhong J, Wu W, Zhu JY, Jiang FX and Wu YL: Stat3 is involved in angiotensin II-induced expression of MMP2 in gastric cancer cells. Dig Dis Sci54: 2056-2062, 2009.
51. Kang J, Bu J, Hao Y and Chen F: Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis8: 274-279, 2005.
52. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y and Kraft AS: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem276: 10767-10774, 2001.
53. Horndasch M and Culig Z: SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells. Prostate71: 1357-1366, 2011.